Advertisement

Predicting coronary heart disease risk using multiple lipid measures

      Principal component analysis was used to summarize variations among 7 lipid measures included in the Framingham Offspring Study (n = 2,694). An overall measure combining information from the 7 lipids was compared with conventional lipid measures in adjusted survival analyses and was found to be a superior predictor of coronary heart disease risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pedersen T.R.
        Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management.
        Am J Cardiol. 2001; 87: 8B-12B
        • Assmann G.
        Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management.
        Am J Cardiol. 2001; 87: 2B-7B
        • Sniderman A.D.
        • Furberg C.D.
        • Keech A.
        • Van Lennep J.E.R.
        • Frohlich J.
        • Jungner I.
        • Walldius G.
        Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.
        Lancet. 2003; 361: 777-780
        • Sniderman A.D.
        • St-Pierre A.C.
        • Cantin B.
        • Dagenais G.R.
        • Despres J.P.
        • Lamarche B.
        Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
        Am J Cardiol. 2003; 91: 1173-1177
      1. Dunteman GH. Principal Components Analysis. Sage University Paper Series on Quantitative Applications in the Social Sciences (No. 07-069). Newbury Park, CA: Sage Publications, 1989:1–96.

        • Kannel W.B.
        • Feinleib M.
        • McNamara P.M.
        • Garrison R.J.
        • Castelli W.P.
        An investigation of coronary heart disease in families: the Framingham Offspring Study.
        Am J Epidemiol. 1979; 110: 281-290
        • Warnick G.R.
        • Benderson J.
        • Albers J.J.
        Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.
        Clin Chem. 1982; 28: 1379-1388
        • McNamara J.R.
        • Schaefer E.J.
        Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions.
        Clin Chim Acta. 1987; 166: 1-8
        • Schaefer E.J.
        • Lamon-Fava S.
        • Ordovas J.M.
        • Cohn S.D.
        • Schaefer M.M.
        • Castelli W.P.
        • Wilson P.W.F.
        Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study.
        J Lipid Res. 1994; 35: 871-882
        • Schaefer E.J.
        • Lamon-Fava S.
        • Cohn S.D.
        • Schaefer M.M.
        • Ordovas J.M.
        • Castelli W.P.
        • Wilson P.W.F.
        Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.
        J Lipid Res. 1994; 35: 779-792
      2. Kannel WB, Wolf PA, Garrison RJ. Monograph. Section 34: Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements: Framingham Heart Study, 30-Year Follow-Up. Springfield, MA: National Technical Information Service, 1987:1–459.

        • NCEP Expert Panel
        Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497